Alvotech’s U.S. share offering completed and underwriters fully exercised the over-allotment option, bringing total proceeds including shares sold to European professional investors to $165 million

▤ Summary

Alvotech completed a U.S. share offering and raised about $165 million in gross proceeds, including shares sold to European professional investors. The company priced the shares at $3.75 and the underwriters fully exercised their option to buy additional shares. Alvotech plans to use the proceeds to fund development of biosimilar medicines, working capital, operating expenses, clinical and preclinical research, manufacturing, and debt repayment or refinancing. The offering increases its outstanding share count and strengthens its balance sheet as it continues building its biosimilar pipeline and commercialization efforts.

$ Funding

▦ Linked Companies